Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Any patient >= 18 years of age
Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies
Disqualifiers
Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Trial population
Adult cancer patients who have already started or are planning to start cancer treatment
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
Non-Interventional Study
Other interventionNon-interventional study
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: Observational1 intervention
Trial outcomes
Primary outcomes
1
In vitro measurement of cellular viability in response to chemotherapy
Will be compared between cells derived from patients who experienced treatment-induced toxicity to cells derived from patients who received the same cancer therapy without toxicity. Statistical analyses of different endpoints will use Fisher's exact test, one-way ANOVA test followed by all-pairwise-multiple-comparison procedures, or an unpaired, two-tailed Student's t-test with significant differences defined by P \< 0.05.
Time frame
Blood drawn at enrollment to obtain sampleSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov